Superworth

ClearPoint Neuro price to book ratio CLPT

Market value divided by the book value of the company's net assets, since 2016.

Today, Nov 2, 2026
11.7×
10-year median
8.7×
Against its 10-year history
60th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.3× to 192×
Peer median
2.3×

ClearPoint Neuro's price to book ratio is 11.7× as of Nov 2, 2026.

That is above its ten-year median of 8.7×, close to the middle of its last ten years.

Over that time it ranged from 2.3× in Sep 2017 to 192× in Apr 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 2.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.7×9.2×44.0×
202525.1×12.0×39.4×
202415.0×4.3×15.0×
20236.9×4.2×7.1×
20225.2×3.9×9.4×
20216.0×6.0×192×
202078.1×8.4×95.7×
201912.7×7.0×100×
20187.5×3.6×8.6×
20173.9×2.3×22.9×
201621.4×13.3×25.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest ClearPoint Neuro's size, closest first, today.

CompanyPrice to book ratio
CLPTClearPoint Neuro11.7×
EMBCEmbectan/m
INFUInfuSystem4.7×
UTMDUtah Medical Products1.8×
TCMDTactile Systems Technology2.3×
PDEXPro DEX3.7×
MOVMovado1.4×
IRMDIradimed9.5×
KEQUKewaunee Scientific1.3×
IARTIntegra Lifesciences1.0×
BVSBioventus4.8×
Peer median2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on ClearPoint Neuro

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.